招聘简介：

合同期限：3年

Petsalaki小组研究人类细胞信号传递，旨在了解在不同环境、组织和条件下控制不同细胞反应的因素。我们分析和整合不同的“组学”数据集（重点是磷蛋白组学和蛋白质组学），以提取和比较上下文特定的信号网络。更多信息请访问：Petsalaki

Zaugg小组调查了个体间分子表型的变化及其遗传和表观遗传变异，目的是更好地了解复杂遗传疾病的分子基础和个体间药物反应的差异。我们在计算调控基因组学、转录组学和数据整合方面拥有强大的专业知识。更多信息请访问：Zaugg

英文原文：

Contract Duration: 3 years

The Petsalaki group studies human cell signalling with the aim to understand what controls different cell responses in different environments, tissues and conditions. We analyse and integrate diverse 'omics' datasets (with emphasis on phosphoproteomics and proteomics), to extract and compare context-specific signalling networks. More info at: Petsalaki

The Zaugg group investigates the variation of molecular phenotypes among individuals along with their genetic and epigenetic variation with the aim of better understanding the molecular basis of complex genetic diseases and inter-individual differences in drug response. We have strong expertise in computational regulatory genomics, transcriptomics and data integration. More info at: Zaugg

Your role

Combination therapies aimed at inhibiting multiple targets or cancer pathways can combat resistance and exploit new actionable dependencies in defined genetic contexts. The candidate will work as part of collaborative team to unlock the potential of rational target/pathway combinations in oncology through ambitious integrative network biology and large-scale functional genomics screens.

You will handle very large and diverse omics datasets, ranging from genomics to phosphoproteomics, as well as CRIPSR perturbation data. You will integrate such data and analyse it using advanced statistical approaches, as well as network modelling to identify cell network rewiring upon perturbation and predict combination targets. You are expected to work independently and will be the main driver of the project. You will be employed at EMBL-EBI as part of the Petsalaki group and have a joint appointment with the Zaugg group at EMBL Heidelberg. In addition, you will work tightly with the members of the collaborative project that also includes the team headed by Mathew Garnett at the Sanger institute.

This project is funded by Open Targets which is a public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. This project will involve scientific teams from the Sanger Institute, European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory (EMBL) and multiple pharmaceutical companies working collaboratively to develop new combination therapies for cancer.

You have

Strong background and skills in large scale data analysis preferably using biological data

Excellent knowledge of advanced statistics

Excellent ability to communicate in written and oral English and work in a team

Excellent programming skills preferably in python and R

High enthusiasm for mining data for generating biological hypotheses

You might also have

The skills below are not necessary but would be an asset:

Experience in network modelling

Background knowledge in epigenetics, gene regulatory networks and/or cell signalling